Patrick Jordan
Chief Executive Officer at Mycovia Pharmaceuticals, Inc.
Profile
Patrick Jordan, Managing Partner and Chief Operating Officer at NovaQuest Capital Management has over 25 years of leadership in the healthcare industry across life sciences, data and analytics, payers and providers and specialty financing.
Mr. Jordan currently serves as the interim Chief Executive Officer of Mycovia Pharmaceuticals, a NovaQuest portfolio company, and led the company to develop the first FDA-approved medication for an unmet medical need in women’s health.
An original member of the NovaQuest unit at its inception at Quintiles, Mr. Jordan originated, structured, and managed biopharma investments in the United States and on assignment to the United Kingdom.
Over a 20-year career at Quintiles (now IQVIA), he led the company’s global accounts, oversaw over $1bn in annual client engagements, and instituted a managed partnership strategy that was recognized in Harvard Business Review.
He was instrumental in the launch and leadership of a new business vertical servicing healthcare provider systems with health information analytics and technology services.
In 2016, he led the transformation of clinical development with data analytics and global delivery processes, which was core to the $18bn merger of Quintiles and IMS Health.
Rejoining NovaQuest in 2017, he leads the firm’s operations and is a member of the investment committee of the General Partner of NovaQuest Pharma Opportunities Fund V.
Mr. Jordan earned a BA from Duke University, MA from the University of Durham, United Kingdom MBA with a concentration in Health Sector Management from the Fuqua School of Business at Duke University.
Patrick Jordan active positions
Companies | Position | Start |
---|---|---|
NovaQuest Capital Management LLC
NovaQuest Capital Management LLC Investment ManagersFinance NovaQuest Capital Management LLC (NovaQuest Capital Management) is a private equity firm founded in 2010 by John Layton Bradley and Jonathan Edward Tunnicliffe. The firm is headquartered in Raleigh, North Carolina. | Chief Operating Officer | 2017-07-31 |
Mycovia Pharmaceuticals, Inc.
Mycovia Pharmaceuticals, Inc. BiotechnologyHealth Technology Mycovia Pharmaceuticals, Inc. develops novel drugs in areas of unmet medical need, with an initial focus in women?s health. Its product candidate, VT-1161, engages in developed as a treatment for recurrent vulvovaginal candidiasis. The company was founded in 2018 and is headquartered in Durham, NC. | Chief Executive Officer | - |
Former positions of Patrick Jordan
Companies | Position | End |
---|---|---|
Quintiles Capital Solutions
Quintiles Capital Solutions Investment ManagersFinance Quintiles Capital Solutions (Quintiles Capital) is a venture capital firm founded in 2000. The firm is headquartered in Durham, North Carolina. | Chief Operating Officer | 2014-07-29 |
Training of Patrick Jordan
Sheffield Hallam University | Masters Business Admin |
The University of Liverpool | Undergraduate Degree |
The University of Newcastle | Graduate Degree |
The Fuqua School of Business | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 3 |
---|---|
Quintiles Capital Solutions
Quintiles Capital Solutions Investment ManagersFinance Quintiles Capital Solutions (Quintiles Capital) is a venture capital firm founded in 2000. The firm is headquartered in Durham, North Carolina. | Finance |
NovaQuest Capital Management LLC
NovaQuest Capital Management LLC Investment ManagersFinance NovaQuest Capital Management LLC (NovaQuest Capital Management) is a private equity firm founded in 2010 by John Layton Bradley and Jonathan Edward Tunnicliffe. The firm is headquartered in Raleigh, North Carolina. | Finance |
Mycovia Pharmaceuticals, Inc.
Mycovia Pharmaceuticals, Inc. BiotechnologyHealth Technology Mycovia Pharmaceuticals, Inc. develops novel drugs in areas of unmet medical need, with an initial focus in women?s health. Its product candidate, VT-1161, engages in developed as a treatment for recurrent vulvovaginal candidiasis. The company was founded in 2018 and is headquartered in Durham, NC. | Health Technology |
- Stock Market
- Insiders
- Patrick Jordan